Aridis Pharmaceuticals, Inc. Share Price

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets 20:38:29 16/07/2024 BST 5-day change 1st Jan Change
0.0649 USD -0.08% Intraday chart for Aridis Pharmaceuticals, Inc. -2.99% -7.42%
Sales 2021 1.54M 118M Sales 2022 3.09M 238M Capitalization 29.39M 2.26B
Net income 2021 -42M -3.23B Net income 2022 -30M -2.31B EV / Sales 2021 13.4 x
Net cash position 2021 12.12M 933M Net Debt 2022 1.25M 96.57M EV / Sales 2022 9.91 x
P/E ratio 2021
-0.62 x
P/E ratio 2022
-0.73 x
Employees 37
Yield 2021 *
-
Yield 2022
-
Free-Float 81.95%
More Fundamentals * Assessed data
Dynamic Chart
Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments CI
Aridis Pharmaceuticals, Inc. announced that it expects to receive $0.299 million in funding CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index CI
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301 CI
More news
1 day-0.08%
1 week-2.99%
Current month+30.32%
1 month-5.53%
3 months-1.67%
6 months-11.22%
Current year-7.42%
More quotes
1 week
0.05
Extreme 0.045
0.07
1 month
0.03
Extreme 0.0312
0.08
Current year
0.03
Extreme 0.0312
0.09
1 year
0.03
Extreme 0.0312
0.30
3 years
0.03
Extreme 0.0312
7.69
5 years
0.00
Extreme 0
12.40
10 years
0.00
Extreme 0
13.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 31/12/02
Founder 75 31/12/02
Director of Finance/CFO 57 -
Members of the board TitleAgeSince
Director/Board Member 79 31/03/15
Founder 75 31/12/02
Chief Executive Officer 60 31/12/02
More insiders
Date Price Change Volume
16/07/24 0.0649 -0.08% 168,442
15/07/24 0.065 +8.25% 83,841
12/07/24 0.06 +8.89% 248,779
11/07/24 0.0551 -17.58% 152,688
10/07/24 0.0668 -4.50% 44,426

Delayed Quote OTC Markets, July 16, 2024 at 08:38 pm

More quotes
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
More about the company